MX2021007477A - Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in the treatment of cancer. - Google Patents

Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in the treatment of cancer.

Info

Publication number
MX2021007477A
MX2021007477A MX2021007477A MX2021007477A MX2021007477A MX 2021007477 A MX2021007477 A MX 2021007477A MX 2021007477 A MX2021007477 A MX 2021007477A MX 2021007477 A MX2021007477 A MX 2021007477A MX 2021007477 A MX2021007477 A MX 2021007477A
Authority
MX
Mexico
Prior art keywords
inhibitor
treatment
cdk4
cancer
combination therapy
Prior art date
Application number
MX2021007477A
Other languages
Spanish (es)
Inventor
Giordano Caponigro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2021007477A publication Critical patent/MX2021007477A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a pharmaceutical combination comprising (a) a Raf inhibitor as defined herein, or a pharmaceutically acceptable salt thereof and (b) a CKD4/6 inhibitor, particularly ribociclib, particularly for use in the treatment of a proliferative disease, preferably melanoma or pancreatic ductal adenocarcinoma.
MX2021007477A 2018-12-20 2019-12-18 Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in the treatment of cancer. MX2021007477A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782767P 2018-12-20 2018-12-20
US201962793128P 2019-01-16 2019-01-16
PCT/IB2019/060987 WO2020128878A1 (en) 2018-12-20 2019-12-18 Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2021007477A true MX2021007477A (en) 2021-08-05

Family

ID=69165429

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007477A MX2021007477A (en) 2018-12-20 2019-12-18 Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in the treatment of cancer.

Country Status (12)

Country Link
EP (1) EP3897591A1 (en)
JP (1) JP2022514056A (en)
KR (1) KR20210105388A (en)
CN (1) CN113453671A (en)
AU (1) AU2019407159A1 (en)
BR (1) BR112021011699A2 (en)
CA (1) CA3123510A1 (en)
CL (1) CL2021001623A1 (en)
IL (1) IL283937A (en)
MX (1) MX2021007477A (en)
TW (1) TW202038964A (en)
WO (1) WO2020128878A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021229439A1 (en) * 2020-05-12 2021-11-18 Novartis Ag Therapeutic combinations comprising a craf inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091876A1 (en) * 2012-07-26 2015-03-04 Novartis Ag PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
CN108348513A (en) * 2015-08-28 2018-07-31 诺华股份有限公司 The combination of RIBOCICLIB and dabrafenib for treating or preventing cancer
EP3618875B1 (en) * 2017-05-02 2023-04-05 Novartis AG Combination therapy comprising a raf inhibitor and trametinib

Also Published As

Publication number Publication date
TW202038964A (en) 2020-11-01
WO2020128878A1 (en) 2020-06-25
JP2022514056A (en) 2022-02-09
BR112021011699A2 (en) 2021-09-08
CL2021001623A1 (en) 2022-02-11
KR20210105388A (en) 2021-08-26
IL283937A (en) 2021-07-29
EP3897591A1 (en) 2021-10-27
CN113453671A (en) 2021-09-28
AU2019407159A1 (en) 2021-07-15
CA3123510A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
MX2021004639A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors.
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2021013830A (en) Ezh2 inhibitors for treating lymphoma.
MX2022010270A (en) A novel approach for treatment of cancer using immunomodulation.
WO2016025635A3 (en) Combination therapy for treating cancer
MX2017014338A (en) Targeted selection of patients for treatment with cortistatin derivatives.
SG10201902664RA (en) Combination therapy for treating cancer
MX2018013387A (en) Arginase inhibitors and their therapeutic applications.
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
MX2018006674A (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor.
MX2021001807A (en) Combination of histone deacetylase inhibitor and protein kinase inhibitor and pharmaceutical use thereof.
MX2021002321A (en) Novel methods.
WO2016043874A3 (en) Combination therapy for treating cancer
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
MX2019015207A (en) Tinostamustine for use in treating ovarian cancer.
MX2019002108A (en) Combination therapy with glutaminase inhibitors.
MY201580A (en) Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor
MX2018015172A (en) Methods of treating pancreatic cancer.
MX2019015676A (en) Use of isovalerylspiramycin i, ii and/or iii in preparation of drug for treating and/or preventing tumour, and drug.
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
MX2021015770A (en) Macrocyclic inhibitors of mcl-1.
PH12020551543A1 (en) Therapeutic modulators of the reverse mode of atp synthase
MX2022014792A (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same.
MX2023001425A (en) Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer.